Literature DB >> 17903209

Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.

H Zetterberg1, J Jacobsson, L Rosengren, K Blennow, P M Andersen.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative syndrome with familial and sporadic forms. Most ALS-associated mutations are found in the superoxide dismutase 1 (SOD1) gene. We conducted a study including 60 sporadic and 19 familial ALS patients, 206 reference patients with other neurological disorders and 40 age- and sex-matched healthy controls to test the hypothesis that cerebrospinal fluid (CSF) levels of neurofilament light (NF-L) protein, a marker of axonal degeneration, might provide diagnostic and prognostic information on the disease. All ALS patients were screened for SOD1 mutations. Ten of the familial and five of the sporadic cases carried SOD1 mutations. NF-L concentration [median (range)] was strongly elevated in ALS [2110 (255-10 800) ng/l] compared with reference patients and healthy controls [277 (<125-15 506) and 175 (<125-710) ng/l, respectively, P < 0.001] and correlated inversely with disease duration (Spearman R = -0.518, P = 0.001). NF-L levels were lower in SOD1 mutation-associated ALS compared with SOD1 wild-type (wt) ALS (P = 0.03). In conclusion, CSF NF-L levels may provide both diagnostic and prognostic information, particularly in SOD1 wt ALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17903209     DOI: 10.1111/j.1468-1331.2007.01972.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  38 in total

1.  Novel CSF biomarkers for frontotemporal lobar degenerations.

Authors:  W T Hu; A Chen-Plotkin; M Grossman; S E Arnold; C M Clark; L M Shaw; L McCluskey; L Elman; H I Hurtig; A Siderowf; V M-Y Lee; H Soares; J Q Trojanowski
Journal:  Neurology       Date:  2010-11-03       Impact factor: 9.910

Review 2.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 3.  Biomarkers in frontotemporal lobar degenerations--progress and challenges.

Authors:  William T Hu; John Q Trojanowski; Leslie M Shaw
Journal:  Prog Neurobiol       Date:  2011-04-30       Impact factor: 11.685

Review 4.  Recent advances in phosphoproteomics and application to neurological diseases.

Authors:  Justine V Arrington; Chuan-Chih Hsu; Sarah G Elder; W Andy Tao
Journal:  Analyst       Date:  2017-11-20       Impact factor: 4.616

Review 5.  The application of biomarkers in clinical trials for motor neuron disease.

Authors:  Jeban Ganesalingam; Robert Bowser
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

Review 6.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 7.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

Review 8.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

9.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

Authors:  Henrik Zetterberg; Tobias Skillbäck; Niklas Mattsson; John Q Trojanowski; Erik Portelius; Leslie M Shaw; Michael W Weiner; Kaj Blennow
Journal:  JAMA Neurol       Date:  2016-01       Impact factor: 18.302

Review 10.  Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.

Authors:  Zahra Alirezaei; Mohammad Hossein Pourhanifeh; Sarina Borran; Majid Nejati; Hamed Mirzaei; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.